胰酶(Viatris Pharmaceutical)(Pancrelipase(Viatris Pharmaceutical)) - 在研适应症：胰腺疾病_专利_临床

概要

基本信息

药物类型

酶

别名

LipaCreon、リパクレオン

靶点-

作用机制

胰酶替代物

治疗领域

消化系统疾病

在研适应症

胰腺疾病

非在研适应症-

原研机构

Viatris Pharmaceutical GK

在研机构

Viatris Pharmaceutical GK

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (2011-04-22),

胰腺疾病

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与胰酶(Viatris Pharmaceutical) 相关的临床试验

JPRN-UMIN000012796 / CompletedIIT

The effect of Lipacreon on the postoperative weight loss and the fecal consistency in patients after gastrectomy for gastric cancer - The effect of Lipacreon on the postoperative weight loss and the fecal consistency in patients after gastrectomy for gastric cancer

开始日期2014-02-01

申办/合作机构-

JPRN-UMIN000006842 / RecruitingIIT

The effect of Lipacreon on the nutritional status and the fecal consistency in patients after total gastrectomy - The effect of Lipacreon on the nutritional status and the fecal consistency in patients after total gastrectomy

开始日期2012-04-01

申办/合作机构-

NCT01427725 / CompletedN/A

Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis, Pancreatectomy and Other Conditions Except Cystic Fibrosis

This study aims at collecting the information related to the safety and effectiveness in the pancreatic exocrine insufficiency patients receiving the treatment with LipaCreon for a long term in order to evaluate the effective and safe use of LipaCreon.

开始日期2011-09-01

申办/合作机构

Mylan, Inc.

100 项与胰酶(Viatris Pharmaceutical) 相关的临床结果

登录后查看更多信息

100 项与胰酶(Viatris Pharmaceutical) 相关的转化医学

登录后查看更多信息

100 项与胰酶(Viatris Pharmaceutical) 相关的专利（医药）

登录后查看更多信息

4

项与胰酶(Viatris Pharmaceutical) 相关的文献（医药）

2022-06-01·Medical Oncology

Effects of an enteral nutrient-rich therapy with omega-3 fatty acids in patients with unresectable or recurrent biliary tract cancer or pancreatic cancer during chemotherapy: a case–control study

Article

作者: Abe, Kyohei ; Shirai, Yoshihiro ; Onda, Shinji ; Hamura, Ryoga ; Gocho, Takeshi ; Ikegami, Toru ; Furukawa, Kenei ; Uwagawa, Tadashi ; Yasuda, Jungo ; Shiozaki, Hironori

AbstractTo evaluate omega-3 fatty acid-rich enteral nutrient effects in patients with unresectable or recurrent biliary tract or pancreatic cancers during chemotherapy. Enteric nutritional supplements containing omega-3 fatty acids (Racol®) was administered to aforementioned patients with cancers during chemotherapy. The skeletal muscle mass and blood test data were obtained pre-administration and 28 and 56 days after. Patients with pancreatic cancer were administered the digestive enzyme supplement pancrelipase (LipaCreon®) 28 days after the start of Racol® administration. The number of chemotherapies skipped due to neutropenia was recorded for 2 months before and after enteral nutrient initiation. In all 39 patients, the skeletal muscle mass increased on day 56 versus baseline (median 17.3 kg vs. 14.8 kg, p < 0.01), number of chemotherapies skipped decreased (mean: 0.65 times/month vs. 1.3 times/month, p = 0.03), and retinol-binding protein (mean: 2.56 mg/dL vs. 2.42 mg/dL, p = 0.05) increased. Patients with pancreatic cancer showed increased blood eicosapentaenoic acid concentration on day 56 versus baseline (median: 48.1 μg/mL vs. 37.0 μg/mL, p = 0.04) and increased skeletal muscle mass (median 16.8 kg vs. 14.4 kg, p = 0.006). Baseline median neutrophil count increased significantly from 2200/μL at baseline to 2500/μL (p = 0.04). Patients with biliary tract cancer during chemotherapy also exhibited increased skeletal muscle mass following omega-3 supplementation (median 17.3 kg vs. 15.8 kg, p = 0.01). In patients undergoing chemotherapy for unresectable or post-recurrence pancreatic and biliary tract cancers, high-omega-3 fatty acid nutrition therapy use improved skeletal muscle maintenance and chemotherapy dosing intensity.

2018-03-28·Anticancer Research4区 · 医学

Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy

4区 · 医学

Article

作者: Takano, Yuki ; Haruki, Koichiro ; Abe, Kyohei ; Yanaga, Katsuhiko ; Sakamoto, Taro ; Gocho, Takeshi ; Onda, Shinji ; Uwagawa, Tadashi

BACKGROUND/AIMOmega-3 fatty acids may improve cancer cachexia, but only in patients with pancreatic and bile duct cancer. Patients with pancreatic cancer commonly suffer from exocrine pancreatic insufficiency, and the ingestion of digestive enzyme supplements may improve absorption.PATIENTS AND METHODSRacol®, an enteral nutrient formulated with omega-3 fatty acids, was administered to patients with unresectable pancreatic and bile duct cancer. The skeletal muscle mass and blood test data were taken pre-administration and at 4 and 8 weeks after. Patients with pancreatic cancer were given the digestive enzyme supplement LipaCreon® from the fifth week after the start of administration.RESULTSIn all 27 patients, skeletal muscle mass was significantly increased at both 4 and 8 weeks after the start of administration versus pre-administration (p=0.006, p=0.002, respectively).CONCLUSIONOmega-3 fatty acid supplementation in patients with unresectable pancreatic and bile duct cancer may improve cancer cachexia.

RSC Advances3区 · 化学

A novel silica-supported polyether polysiloxane quaternary ammonium demulsifier for highly efficient fine-sized oil droplet removal of oil-in-water emulsions

3区 · 化学

ArticleOA

作者: Wu, Mian ; Zhai, Mengjin ; Li, Xiaobing ; Wang, Cunying

The existence of fine-sized oil drops that are difficult to coalesce greatly decreases the separation efficiency of produced water from alkali, surfactant, and polymer flooding technology (ASP) containing oil-in-water emulsions.

100 项与胰酶(Viatris Pharmaceutical) 相关的药物交易

登录后查看更多信息